Staphylococcus (e.g., Staphylococcus Aureus, Etc.) Patents (Class 514/2.7)
  • Patent number: 10406204
    Abstract: The present invention provides an antimicrobial peptide polymer comprising at least one monomer which is digested by pepsin, a multimeric antimicrobial peptide complex comprising the polymer and a cell surface anchoring motif linked to the polymer, an antimicrobial microorganism displaying the multimeric antimicrobial peptide complex, an antimicrobial composition comprising the same, a method of treating an infectious disease caused by bacteria, yeast or fungi by administering the antimicrobial composition, and a method for producing the antimicrobial microorganism. According to the invention, living microorganisms displaying an antimicrobial peptide on the cell surface thereof may be administered in vivo without having to lyse the microbial cell and isolate and purify the antimicrobial peptide, so that the antimicrobial peptide exhibits antimicrobial activity. Thus, the antimicrobial peptide may be produced at significantly reduced costs so that it may have widespread use.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: September 10, 2019
    Assignees: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, INTELLIGENT SYNTHETIC BIOLOGY CENTER
    Inventors: Sun-Chang Kim, Ju Ri Shin, Ki Jung Lim, Da Jung Kim, Young Woong Lee, Su A Jang, Bong Hyun Sung
  • Patent number: 9205097
    Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analog. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA).
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: December 8, 2015
    Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
    Inventors: Michael R. Yeaman, Arnold S. Bayer
  • Publication number: 20150148286
    Abstract: Provided are compositions and methods for potentiating the effect of antibiotics. The compositions comprise a non-covalent complex of alpha-lactalbumin and fatty acid. The fatty acids are cis, unsaturated, C14 to C20 fatty acids. The complex and antibiotic can be administered to an individual together or separately. The antibiotic may be one to which resistance has developed.
    Type: Application
    Filed: July 5, 2013
    Publication date: May 28, 2015
    Inventors: Anders P. Hakansson, Laura R. Marks, Hazeline Hakansson
  • Publication number: 20150132310
    Abstract: The present invention relates to methods of treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection a subject that involves administering a CD11b inhibitor. The present invention further relates to a non-human transgenic animal expressing human CD11b and its use in methods of identifying novel therapeutics for the treatment and prevention of Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 14, 2015
    Applicant: NEW YORK UNIVERSITY
    Inventors: Victor J. Torres, Ashley L. Dumont
  • Publication number: 20150104492
    Abstract: The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced inflammation and for stimulating wound healing via the synthetic antibacterial peptides. Further provided is a device having a surface with a coating comprising the synthetic antibacterial peptides.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventors: Alison McDermott, Marialuisa Mangoni
  • Patent number: 9006392
    Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: April 14, 2015
    Assignee: Novacta Biosystems Limited
    Inventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
  • Publication number: 20150099694
    Abstract: Devices, systems, and methods for strain-specific identification and assessment of susceptibility of microorganisms based on the response of sensors in a colorimetric sensor array to metabolic products of the microorganism.
    Type: Application
    Filed: April 26, 2013
    Publication date: April 9, 2015
    Applicant: Specific Technologies LLC
    Inventors: Sung Hyun Lim, Raymond Anthony Martino, Paul A. Rhodes
  • Patent number: 8999922
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: April 7, 2015
    Assignee: RQX Pharmaceuticals, Inc.
    Inventors: Robert I. Higuchi, Tucker Curran Roberts, Peter Andrew Smith, David Campbell, Prasuna Paraselli
  • Publication number: 20150080291
    Abstract: Disclosed are peptides having biological and therapeutic activity. Particularly disclosed are lipidated di- or tri-peptides analogs of KPV or KdPT that exhibit antimicrobial activity. In particular, the peptides of this invention provide enhanced anti-microbial activity over the base tri-peptides, lysine-proline-valine and lysine-d-proline-tyrosine. The disclosed peptides have the general formula of C12-18 lipid-KXZ-NH2i wherein K is lysine; X is proline, d-proline, histidine or arginine; Z is optional and if present Z is valine, threonine, alanine or leucine; and the terminal COOH is NH2 amidated. The C12-18 lipid is preferably the lipid moiety of lauric acid (C12), myristic acid (C14), pentadecanoic acid (C15), palmitic acid (C16), or stearic acid (C18). The invention is further related to methods of using of these peptides to treat various insults, inflammations or bacterial infections affecting the skin and other related mucosal body surfaces such as the oral cavity.
    Type: Application
    Filed: March 7, 2013
    Publication date: March 19, 2015
    Inventors: Lijuan Zhang, Robin Carmichael
  • Publication number: 20150080289
    Abstract: Disclosed are amphiphilic peptides. Also disclosed are methods of treating proliferative disease, bacterial infection, viral infection and fungal infection, endotoxin neutralization and a method of removing biofilm. Also disclosed is the use of the amphiphilic peptides.
    Type: Application
    Filed: August 29, 2013
    Publication date: March 19, 2015
    Inventors: Yi-Yan Yang, Zhan Yuin Ong
  • Publication number: 20150072922
    Abstract: Described herein are compounds and compositions comprising antimicrobial peptides and methods for their use.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 12, 2015
    Inventors: David Hains, Andrew Schwaderer, Huanyu Wang
  • Publication number: 20150065415
    Abstract: In part, the present disclosure is directed to prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide compounds with significant solubility and bioavailability profiles.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Inventors: John J. Partridge, John Colucci, Yves Gareau, Michel Therien, Robert Zamboni, Barry Hafkin, Anthony Marfat, Helmi Zaghdane
  • Publication number: 20150065414
    Abstract: The present invention provides modified TLR2 ligands useful for modulating inflammatory responses. In particular, the ligands comprise (a) a fatty acid di- or tri-linoleate and (b) a GM1-binding peptide. The linoleate provides the anti-inflammtory function, while the GM1-binding peptide facilitates endocytosis.
    Type: Application
    Filed: August 30, 2012
    Publication date: March 5, 2015
    Applicant: UTI LIMITED PARTNERSHIP
    Inventors: Elizabeth M. Long, Stephen M. Robbins, Paul Kubes, Ela Kolaczkowska
  • Publication number: 20150045286
    Abstract: Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided.
    Type: Application
    Filed: March 8, 2013
    Publication date: February 12, 2015
    Inventors: Floyd E. Romesberg, Peter A. Smith, Tucker C. Roberts
  • Publication number: 20150038407
    Abstract: The present invention relates to novel agents, pharmaceutical compositions containing them, and theft use in therapy, particularly anti-microbial and anti-cancer therapy. In particular, the present invention relates to novel peptide-based compounds based on SEQ ID NO: 40 which have surprisingly been shown to have inhibitory effects on the growth and/or viability of cells, particularly bacterial and cancer cells. Also provided are therapeutic and non-therapeutic methods which include the use of peptides of the invention.
    Type: Application
    Filed: June 16, 2014
    Publication date: February 5, 2015
    Inventor: Lars Prestegarden
  • Patent number: 8940687
    Abstract: Antimicrobial compositions based upon stabilized angiogenin compositions also contain osteopontin and antimicrobial proteins such as lactoperoxidase (LPO), myeloperoxidase (MPO), salivary peroxidase (SPO) and lysozyme.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: January 27, 2015
    Assignee: Naidu LP
    Inventors: A. Satyanarayan Naidu, A. G. Tezus Naidu, A. G. Sreus Naidu
  • Patent number: 8936782
    Abstract: The present invention describes method of treating bacterial infections, including MRSA. In various embodiments, the methods can use interferon beta, which is found to have antimicrobial activity. In certain embodiments, the interferon beta can be human interferon beta. In other embodiments, the interferon beta can be mouse interferon beta. In further embodiments, the interferon beta can be human interferon beta containing amino acid substitutions to make the human interferon beta more cationic in neutral pH.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: January 20, 2015
    Assignee: Cedars-Sinai Medical Center
    Inventors: David M. Underhill, George Y. Liu, Amber Kaplan
  • Publication number: 20150018268
    Abstract: The present invention relates to the use of a multivalent synthetic compound, which is significantly more resistant to at least one protease than a standard peptide bond, for preparing a medication, and methods of use for the treatment of diseases, e.g., due to bacterial and/or microbial growth.
    Type: Application
    Filed: October 4, 2011
    Publication date: January 15, 2015
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ELRO PHARMA, UNIVERSITE PARIS 12 - VAL DE MARNE
    Inventors: Robert H. Zimmer, José Courty
  • Publication number: 20150018269
    Abstract: The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases.
    Type: Application
    Filed: August 24, 2012
    Publication date: January 15, 2015
    Applicants: UNIVERSITÄT ZU KÖLN, FORSCHUNGSVERBUND BERLIN E.V.
    Inventors: Ronald Kühne, Hartmut Oschkinat, Robert Opitz, Matthias Müller, Hans-Günther Schmalz, Cedric Reuter, Peter Huy
  • Publication number: 20150011465
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.
    Type: Application
    Filed: September 9, 2014
    Publication date: January 8, 2015
    Inventors: Kent Kirshenbaum, Sung Bin Shin
  • Publication number: 20150005228
    Abstract: Disclosed is the method of treating keratits in a subject thereof comprising administering into the subject an amphiphilic peptides of the present disclosure. Also disclosed are methods of removing biofilm from cornea.
    Type: Application
    Filed: July 1, 2014
    Publication date: January 1, 2015
    Inventors: Yi-Yan Yang, Zhan Yuin Ong
  • Patent number: 8901071
    Abstract: The present invention relates to peptides and their use in the treatment of microbial infections, in particular bacterial infections. In particular, the invention relates to peptides wherein at least 75% of the amino acids of the peptide are arginine and phenylalanine amino acids, at least 50% of the amino acids being arginine amino acids and at least 15% of the amino acids being phenylalanine amino acids.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: December 2, 2014
    Assignee: Novabiotics Limited
    Inventors: Deborah O'Neil, Derry Mercer, Cedric Charrier
  • Publication number: 20140349918
    Abstract: The present invention relates to xanthone analogs. Such compounds may be used in the treatment of bacterial infections.
    Type: Application
    Filed: September 10, 2012
    Publication date: November 27, 2014
    Applicants: Singapore Health Services Pte Ltd., Agency for Science, Technology and Research
    Inventors: Hanxun Zou, Lakshminiarayan Rajanmani, Lei Zhou, Chang Chui Charles Tang, Jun Jie Koh, Tiang Hwee Donald Tan, Chandra Verma, Roger W. Beuerman, Shouping Liu, Saraswathi Padmanabhan
  • Publication number: 20140348919
    Abstract: This invention relates to novel purified compounds of Formula I. The invention includes all stereoisomeric forms and all tautomeric forms of the compounds of Formula I and pharmaceutically acceptable salts and derivatives. The present invention further relates to processes for the production of the novel antibacterial compounds by fermentation of the microorganism belonging to Streptomyces species (PM0626271/MTCC 5447) and to pharmaceutical compositions containing one or more of the novel compounds as active ingredient and their use in medicines for treatment and prevention of diseases caused by bacterial infections.
    Type: Application
    Filed: August 8, 2014
    Publication date: November 27, 2014
    Applicant: PIRAMAL ENTERPRISES LIMITED
    Inventors: PRABHU DUTT MISHRA, GIRISH BADRINATH MAHAJAN
  • Publication number: 20140329739
    Abstract: Disclosed are an antibiotic peptide and the like, having an amino acid sequence of Ac-Phe-Lys-Lys-Leu-Lys-Lys-Leu-Phe-Ser-Lys-Leu-Trp-Asn-Trp-Lys-NH2 (SEQ ID No:1). Also disclosed are a method of preparing the antibiotic peptide and the like, and the application thereof. The antibiotic peptide and the like synthesized by the solid phase synthetic technology according to the present invention can be used as a formulation against microbial infection and as alternate or adjuvant medicaments of antibiotics in the prior art.
    Type: Application
    Filed: January 17, 2012
    Publication date: November 6, 2014
    Applicant: JIANGSU PROTELIGHT PHARMACEUTICAL & BIOTECHNOLOGY CO., LTD.
    Inventors: Yuxin Chen, Mingxia Chen, Yibing Huang, Yang Li, Yong Wang, Lili Qu, Wenren Wang
  • Publication number: 20140329740
    Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA).
    Type: Application
    Filed: March 28, 2014
    Publication date: November 6, 2014
    Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Michael R. YEAMAN, Arnold S. BAYER
  • Publication number: 20140323391
    Abstract: Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.
    Type: Application
    Filed: March 15, 2014
    Publication date: October 30, 2014
    Applicant: Duke University
    Inventors: Ephraim Tsalik, Vance Fowler, Christopher W. Woods, Joseph E. Lucas, Geoffrey S. Ginsburg, Sun Hee Ahn
  • Publication number: 20140322132
    Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 30, 2014
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • Publication number: 20140315788
    Abstract: The present invention encompasses combination comprising a plurality of amino acids, formulations thereof for use in humans and animals, as well as methods for increasing muscle protein synthesis, muscle strength, and/or muscle function.
    Type: Application
    Filed: April 18, 2014
    Publication date: October 23, 2014
    Inventors: Robert R. Wolfe, Jeanne Wei
  • Publication number: 20140315789
    Abstract: The present disclosure relates generally to antimicrobial peptides, methods for their use, and methods for preparing devices having surfaces which are modified to incorporate OH said peptides. In some embodiments, the antimicrobial peptides are antimicrobial OH cationic peptides modified to comprise a thiol functional group.
    Type: Application
    Filed: November 21, 2012
    Publication date: October 23, 2014
    Inventors: Mark Duncan Willcox, Neresh Kumar, Nerida Cole, Renxum Chen
  • Publication number: 20140314823
    Abstract: The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.
    Type: Application
    Filed: May 15, 2014
    Publication date: October 23, 2014
    Applicant: The University of Manchester
    Inventors: Mathew Upton, Stephanie Sandiford
  • Publication number: 20140308347
    Abstract: The present invention relates to compounds that are cationic vancomycin analogues and their compositions. Method of making the compounds and their use as medicament for the treatment of bacterial infection are also disclosed.
    Type: Application
    Filed: November 13, 2012
    Publication date: October 16, 2014
    Applicant: JAWAHARLAL NEHRU CENTRE FOR ADVANCED
    Inventors: Jayanta Haldar, Yarlagadda Venkateswarlu, Padma Akkapeddi
  • Publication number: 20140303071
    Abstract: The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Inventor: Deborah O'NEIL
  • Publication number: 20140303069
    Abstract: Anti-microbial peptides and methods of use are provided.
    Type: Application
    Filed: November 20, 2012
    Publication date: October 9, 2014
    Inventors: Guangshun Wang, Biswajit Mishra
  • Publication number: 20140303072
    Abstract: Disclosed are diagnostic methods for determining a subtype of methicillin-resistant Staphylococcus aureus (MRSA) in a biological sample of a mammal. Methods include providing a biological sample of the mammal, performing a PCR analysis of the biological sample, and analyzing the PCR amplicons with respect to their sizes so as to determine for type I, type II, type III, type IV or type V MRSA that may be present in the biological sample. Further example embodiments include using at least one mecA primer pair and/or using at least one Staphylococcus aureus nuc primer pair in the PCR analysis. Further disclosed are methods for screening populations for MRSA, and methods of treating a mammal testing positive for Type IV MRSA. Also disclosed are kits for determining a MRSA subtype in a mammal and isolated primers that may be used in the present methods and kits.
    Type: Application
    Filed: March 18, 2014
    Publication date: October 9, 2014
    Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Scott Elliot Gygax, Christina Lim Overmyer, Lisa A. DeSalvia, Martin Adelson, Eli Mordechai
  • Publication number: 20140296132
    Abstract: The present invention provides polypeptides, compositions thereof, and methods for use of the polypeptides in treating bacterial infection and for use as disinfectants.
    Type: Application
    Filed: November 1, 2012
    Publication date: October 2, 2014
    Applicant: Arizona Board of Regents of behalf of Arizona State University
    Inventors: Stephen Johnston, Valeriy Domenyuk, Chris Diehnelt
  • Patent number: 8846609
    Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: September 30, 2014
    Assignee: New York University
    Inventors: Victor J. Torres, Derya Unutmaz, Francis Alonzo, III
  • Publication number: 20140286904
    Abstract: An antimicrobial peptide having potent antibacterial activity against Listeria monocytogenes and Staphylococcus aureus is described. Also described is an isolated Lactobacillus salivarius DPC6502 strain as deposited with the National Collection of Industrial and Marine Bacteria under the Accession No. NCIMB 41840, and variants thereof, wherein the isolated bacteria and variants thereof express an antimicrobial peptide of the invention.
    Type: Application
    Filed: July 27, 2012
    Publication date: September 25, 2014
    Applicants: AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY (TEAGASC), UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK
    Inventors: Paul Ross, Eileen O'Shea, Colin Hill
  • Publication number: 20140274879
    Abstract: The present invention encompasses methods for treating an infection and/or treating or reducing inflammation through the administration of a therapeutically effective amount of a peptide to a subject in need thereof. In some aspects, the peptide is a Helicobacter pylori-derived peptide, such as an HPA3NT3 peptide and the infection is a bacterial infection.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS
    Inventors: Peter I. Song, Cheryl Armstrong, Sunhyo Ryu, Yoonkyung Park
  • Publication number: 20140256615
    Abstract: Compounds that affect quorum sensing (QS) in Staphylococcus aureus and related Staphylococcus species (e.g., S. epidermidis). Compounds which modulate one or more of the four AgrC receptors of Staphylococcus species, particularly of Staphylococcus aureus. Modulation includes inhibition or activation of one or more of these four AgrC receptors. These compounds are useful for bacterial interference and are useful for treating bacterial infections, particularly staphylococcal infection. Treatment can include combination of one or more of the compounds of the invention in combination with one or more antibiotics.
    Type: Application
    Filed: December 17, 2013
    Publication date: September 11, 2014
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Helen BLACKWELL, Yftah TAL-GAN, Danielle STACY
  • Publication number: 20140235531
    Abstract: The present invention is directed to the peptides WKWLKKWIK, WRKFWKYLK, and RRWRVIVKW and use of said peptides as therapeutic agents for the prophylaxis and/or treatment of infections, in particular bacterial and/or fungal infections and diseases caused by bacterial and/or fungal infections.
    Type: Application
    Filed: October 10, 2012
    Publication date: August 21, 2014
    Inventor: Dorian Bevec
  • Patent number: 8809263
    Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA).
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: August 19, 2014
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Michael Yeaman, Arnold Bayer
  • Publication number: 20140220086
    Abstract: Antimicrobial compositions including a cell penetrating peptide (CPP) having the amino acid sequence Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Gly-Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Arg (SEQ ID NO:1) or variant thereof are disclosed. The CPP, which itself has antimicrobial properties, can be advantageously combined with or conjugated to a cargo to increase the delivery, efficacy, or combinations thereof, of the cargo into cells. In preferred embodiments, the CPP is combined with or conjugated to a functional nucleic acid, such as an external guide sequence (EGS) which can target and reduce expression of essential microbial genes or genes than impart resistance to antimicrobial drugs. Methods of using the compositions alone or in combination with traditional antimicrobial drugs to treat infections are also disclosed.
    Type: Application
    Filed: September 21, 2012
    Publication date: August 7, 2014
    Inventors: Sidney Altman, Alfred Bothwell, Choukri Mamoum
  • Publication number: 20140213506
    Abstract: The present invention provides methods for preventing, treating, or reducing the severity of infection, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen, so as to prime or enhance a patient's immune response for pathogen exposure. In certain embodiments, the alpha thymosin regimen is scheduled or timed with respect to potential or expected pathogen exposures. The regimen of alpha thymosin peptide as described herein provides the patient with a more robust immune response to pathogen exposure, including higher antibody titers and/or a more rapid antibody response. In certain embodiments, the patient is immunodeficient or immunecompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide helps to protect the patient from, or reduce the severity of nosocomial infection or illness.
    Type: Application
    Filed: February 3, 2012
    Publication date: July 31, 2014
    Inventor: Cynthia W. Tuthill
  • Publication number: 20140205654
    Abstract: The present invention discloses formulations of liposomal vancomycin that are highly effective in the treatment of bacterial infections, and particularly MRSA infections. The present invention further teaches methods of using the formulations disclosed herein for the treatment of bacterial infections. The inventors determined that certain formulations disclosed herein are likely to result in lower toxicity than what is normally associated with vancomycin treatment.
    Type: Application
    Filed: April 26, 2012
    Publication date: July 24, 2014
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: George Y. Liu, Abdel Omri
  • Publication number: 20140206601
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.
    Type: Application
    Filed: February 20, 2014
    Publication date: July 24, 2014
    Applicants: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Jean-Claude Sirard, Jose A. Chabalgoity
  • Patent number: 8785375
    Abstract: The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: July 22, 2014
    Assignee: Novabiotics Ltd.
    Inventor: Deborah O'Neil
  • Publication number: 20140194345
    Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.
    Type: Application
    Filed: December 3, 2013
    Publication date: July 10, 2014
    Inventors: Aaron J. Peoples, Dallas Hughes, Losee Lucy Ling, William Millett, Anthony Nitti, Amy Spoering, Victoria Alexandra Steadman, Jean-Yves Christophe Chiva, Linos Lazarides, Michael Kenyon Jones, Karine Gaelle Poullenec, Kim Lewis
  • Publication number: 20140179594
    Abstract: The present invention provides methods for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria in companion animals and livestock, including Streptococcus and Staphylococcus bacterial strains, including pathogenic and antibiotic-resistant bacteria, and related conditions. The methods of the invention utilize PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of companion animals and livestock are provided.
    Type: Application
    Filed: April 20, 2012
    Publication date: June 26, 2014
    Applicants: THE ROCKEFELLER UNIVERSITY, UNIVERSITEIT UTRECHT HOLDING BV
    Inventors: Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Jacob Anthony Wagenaar, Jan Arend Stegeman
  • Patent number: RE45003
    Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: July 8, 2014
    Assignee: Novacta Biosystems Limited
    Inventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson